Insulin Resistance: The Hidden Metabolic Imbalance That Deserves Our Attention
Understanding how insulin resistance develops, why it matters, and how early intervention can protect long-term metabolic health.
Introduction:
When the Body Stops Responding to Insulin
The human body relies on a remarkably coordinated network of hormones to maintain metabolic balance. Among these, insulin plays a central role in regulating blood glucose levels, energy utilisation and nutrient storage. Yet, long before diabetes develops or blood sugar levels become noticeably abnormal, subtle changes may already be taking place within the body’s metabolic system.
One such change is insulin resistance, a condition in which the body’s cells become less responsive to the effects of insulin. Although frequently associated with type 2 diabetes and obesity, insulin resistance is a broader metabolic disturbance that can affect individuals across different ages, body weights and lifestyles.
What makes insulin resistance particularly important is its often silent progression. An individual may have normal blood glucose levels while the pancreas is working considerably harder to maintain them. Over time, this compensatory mechanism may become insufficient, increasing the likelihood of prediabetes, type 2 diabetes and other metabolic complications.
Understanding insulin resistance is therefore not simply about preventing diabetes. It is about recognising how the body regulates energy, how metabolic disturbances develop and why early lifestyle interventions can have lasting health benefits.
Understanding Insulin: The Hormone Behind Metabolic Balance
Insulin is a peptide hormone produced by the beta cells of the pancreatic islets. Its primary function is to maintain glucose homeostasis by coordinating how the body absorbs, uses and stores nutrients.
Following a meal, carbohydrates are digested into simpler sugars, including glucose, which enters the bloodstream. As blood glucose concentrations rise, the pancreas releases insulin. This hormone binds to specific receptors on target cells, activating intracellular signalling pathways that regulate glucose uptake and metabolism.
In skeletal muscle and adipose tissue, insulin stimulates the movement of glucose transporter type 4 (GLUT4) proteins to the cell membrane, facilitating glucose entry into cells. In the liver, insulin suppresses glucose production and promotes glycogen synthesis. It also influences fat metabolism by reducing the breakdown of stored triglycerides.
Under normal circumstances, these processes maintain blood glucose within a relatively narrow physiological range.
However, when cells become less responsive to insulin, the same amount of hormone produces a weaker biological response. The pancreas initially compensates by secreting additional insulin, a state known as compensatory hyperinsulinaemia.
This adaptation may maintain normal blood glucose for years. Nevertheless, if insulin resistance persists and pancreatic beta-cell function progressively declines, glucose regulation may deteriorate, eventually resulting in prediabetes or type 2 diabetes.
What Causes Insulin Resistance?
Insulin resistance does not arise from a single cause. Rather, it develops through a complex interaction of genetic susceptibility, adipose tissue dysfunction, hormonal influences, inflammation and environmental factors.
One of the strongest contributors is excess visceral adipose tissue, the fat deposited around internal abdominal organs. Unlike subcutaneous fat, visceral adipose tissue is metabolically active and can contribute to increased circulating free fatty acids, altered adipokine secretion and low-grade inflammation.
These changes may interfere with insulin signalling pathways in the liver and skeletal muscles, reducing their responsiveness to insulin.
Physical inactivity also contributes significantly. Skeletal muscle is a major site of insulin-mediated glucose disposal, and regular muscular activity improves glucose uptake and insulin sensitivity. Prolonged sedentary behaviour, particularly when combined with excess energy intake, may therefore contribute to metabolic dysfunction.
Genetic factors influence susceptibility, explaining why insulin resistance can occur even in individuals who are not overweight. Other contributing factors include inadequate sleep, obstructive sleep apnoea, certain endocrine disorders and medications such as glucocorticoids.
Importantly, insulin resistance should not be regarded simply as a consequence of eating too much sugar. Although dietary patterns influence metabolic health, its development involves a much broader interaction between body composition, physical activity, hormonal regulation and inherited risk.
The Silent Progression: Why Symptoms May Go Unnoticed
One of the most challenging aspects of insulin resistance is that it often produces no obvious symptoms during its early stages.
Because the pancreas can compensate by increasing insulin secretion, routine blood glucose measurements may remain within normal limits despite reduced insulin sensitivity.
Some individuals develop clinical features associated with metabolic dysfunction, including increased abdominal adiposity, elevated triglyceride levels, reduced high-density lipoprotein (HDL) cholesterol and hypertension.
A more recognisable physical finding is acanthosis nigricans, characterised by darkened, thickened and velvety skin, commonly affecting the neck, axillae and other skin folds. This finding can be associated with hyperinsulinaemia, although it may have other causes.
Skin tags may also be observed more frequently in people with insulin resistance, but they are not diagnostic.
Fatigue, increased hunger and difficulty managing body weight are sometimes reported. However, these symptoms are nonspecific and should not independently be interpreted as evidence of insulin resistance.
The absence of symptoms does not necessarily indicate the absence of metabolic risk. This is why appropriate screening is particularly important in individuals with recognised risk factors.
Insulin Resistance and Women’s Hormonal Health
Insulin resistance has particular relevance to women’s health because of its relationship with reproductive hormones, ovarian function and changes in body composition throughout life.
One of its most established associations is with polycystic ovary syndrome (PCOS), a common endocrine disorder affecting women of reproductive age.
In many women with PCOS, reduced insulin sensitivity results in compensatory hyperinsulinaemia. Elevated insulin concentrations can stimulate ovarian androgen production and reduce hepatic synthesis of sex hormone-binding globulin (SHBG). These effects may increase circulating free androgen levels, contributing to symptoms such as acne, hirsutism and menstrual irregularities.
Insulin resistance may also contribute to ovulatory dysfunction and the metabolic complications associated with PCOS. However, not every woman with PCOS has the same degree of insulin resistance, and PCOS is not caused solely by abnormal insulin activity.
Pregnancy represents another important physiological context. During normal pregnancy, maternal insulin sensitivity decreases, particularly during the second and third trimesters, partly due to placental and maternal hormonal changes. This adaptation helps ensure adequate nutrient availability for fetal growth.
When pancreatic insulin secretion cannot adequately compensate for the increased insulin resistance, gestational diabetes mellitus may develop. Women with a history of gestational diabetes also have an increased risk of developing type 2 diabetes later in life.
During perimenopause and menopause, changes in oestrogen concentrations, ageing, muscle mass and fat distribution may influence insulin sensitivity. Increased visceral fat accumulation during this transition can contribute to greater cardiometabolic risk.
These relationships highlight the importance of considering metabolic health as an integral part of women’s reproductive and hormonal care.
Insulin Resistance, Fatty Liver and Cardiovascular Health
The consequences of insulin resistance extend beyond glucose metabolism.
In the liver, reduced insulin sensitivity can coexist with continued stimulation of fat synthesis, contributing to hepatic triglyceride accumulation. This process is closely associated with metabolic dysfunction-associated steatotic liver disease (MASLD), previously commonly referred to as non-alcoholic fatty liver disease.
Insulin resistance is also frequently associated with an adverse lipid profile, including elevated triglycerides, reduced HDL cholesterol and changes in lipoprotein metabolism.
When these abnormalities occur alongside central adiposity, elevated blood pressure and impaired glucose regulation, they may form part of the metabolic syndrome, a cluster of factors associated with increased cardiovascular and diabetes risk.
However, these relationships are complex and bidirectional. Insulin resistance is an important component of metabolic dysfunction, but it is not the sole cause of cardiovascular disease or fatty liver disease.
Insulin Resistance and Weight Management: Understanding the Metabolic Connection
Insulin resistance and excess body weight share a complex, bidirectional relationship, with each potentially influencing the other. Insulin plays an essential role not only in regulating blood glucose but also in controlling fat storage, energy utilisation and lipid metabolism. When the body’s cells become less responsive to insulin, the pancreas compensates by producing higher amounts of the hormone, resulting in hyperinsulinaemia. Because insulin normally suppresses fat breakdown and promotes energy storage, persistently elevated insulin levels may influence fat metabolism. However, weight gain is multifactorial, and insulin resistance alone does not necessarily cause obesity or prevent weight loss.
Excess visceral fat, particularly the adipose tissue surrounding abdominal organs, is strongly associated with reduced insulin sensitivity. This metabolically active tissue can release increased amounts of free fatty acids and inflammatory mediators, contributing to impaired insulin signalling in skeletal muscles and the liver. Consequently, a cycle may develop in which excess abdominal adiposity worsens insulin resistance, while associated metabolic and hormonal disturbances complicate weight management.
Weight reduction can significantly improve insulin sensitivity, particularly in individuals with overweight or obesity. Research demonstrates that a sustained reduction of approximately 5–7% of initial body weight can improve metabolic risk factors and substantially reduce progression to type 2 diabetes in high-risk individuals. Even without major weight loss, regular physical activity can improve glucose uptake by skeletal muscles and enhance insulin sensitivity.
Effective weight management in insulin resistance should therefore focus on sustainable lifestyle modifications rather than restrictive dieting or rapid weight-loss strategies. A balanced dietary pattern rich in fibre, vegetables, whole grains, legumes, lean protein and healthy fats, combined with regular aerobic exercise, resistance training and adequate sleep, supports healthier glucose regulation and long-term metabolic wellbeing. Individualised medical management may also be appropriate for people with obesity, prediabetes or associated metabolic conditions.
Importantly, insulin resistance can occur in individuals with a normal body mass index, and not everyone with obesity has the same degree of insulin resistance. The primary objective should be improved metabolic health rather than weight reduction alone, with emphasis on body composition, cardiovascular risk factors, glucose regulation and sustainable lifestyle habits.
How Is Insulin Resistance Diagnosed?
Despite its clinical importance, diagnosing insulin resistance is not as straightforward as measuring blood glucose.
The hyperinsulinaemic-euglycaemic clamp is regarded as a reference method for measuring insulin sensitivity, but its complexity makes it largely unsuitable for routine clinical practice.
Fasting insulin measurements and calculated indices such as the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) are used in research and selected clinical settings. However, differences between laboratory assays, patient populations and the absence of universally accepted diagnostic thresholds limit their routine application.
Consequently, clinical assessment usually focuses on identifying associated metabolic abnormalities and estimating the individual’s risk of developing diabetes and cardiovascular disease.
Commonly recommended investigations include fasting plasma glucose, glycated haemoglobin (HbA1c) and, where appropriate, a 75-g oral glucose tolerance test (OGTT). Lipid profiles, blood pressure, waist circumference and other relevant clinical findings provide additional information about cardiometabolic health.
Importantly, normal glucose or HbA1c results do not completely exclude insulin resistance, because compensatory insulin secretion may maintain normal glucose concentrations during its early stages.
In women with PCOS, international evidence-based guidelines recommend the OGTT as the most accurate method for assessing glycaemic status, while routine insulin assays are not recommended because of their limited clinical usefulness.
The aim of evaluation is not merely to identify an abnormal laboratory value but to understand the patient’s overall metabolic risk.
Can Insulin Resistance Be Improved or Reversed?
The encouraging aspect of insulin resistance is that insulin sensitivity can often improve substantially through appropriate interventions, particularly when metabolic abnormalities are recognised early.
Lifestyle modification remains the foundation of prevention and management.
Regular physical activity is especially valuable because skeletal muscle contractions stimulate glucose uptake through mechanisms that are partly independent of insulin. Over time, exercise improves muscular insulin sensitivity, metabolic flexibility and cardiovascular fitness.
Evidence-based recommendations encourage adults at increased risk of type 2 diabetes to achieve at least 150 minutes of moderate-intensity physical activity per week. Resistance training provides additional benefits by supporting muscle mass and improving glucose metabolism.
Nutrition also plays a central role. Rather than focusing on eliminating individual foods, the emphasis should be on sustainable dietary patterns that support metabolic health.
Diets rich in vegetables, whole grains, legumes, fibre, nuts, appropriate protein sources and unsaturated fats are associated with favourable metabolic outcomes. Reducing sugar-sweetened beverages, excessive refined carbohydrates and highly processed energy-dense foods may also help improve dietary quality and weight management.
Mediterranean-style, plant-based and appropriately structured lower-carbohydrate eating patterns may all be suitable, depending on individual preferences and clinical requirements. There is no single dietary approach that is universally superior for everyone with insulin resistance.
For individuals with overweight or obesity, modest and sustained weight reduction can improve insulin sensitivity and reduce the risk of progression to type 2 diabetes.
The landmark Diabetes Prevention Program demonstrated that intensive lifestyle intervention reduced the incidence of type 2 diabetes by approximately 58% over an average follow-up of 2.8 years in high-risk adults. This finding established the substantial preventive value of dietary changes, physical activity and weight management.
Sleep quality, stress management and reducing prolonged sedentary time are also important components of a comprehensive metabolic health strategy.
The Role of Medication in Insulin Resistance
Although lifestyle interventions remain central, pharmacological treatment may be appropriate in selected individuals.
Metformin is an insulin-sensitising medication that primarily reduces hepatic glucose production and improves glucose regulation. It is widely used in type 2 diabetes and may be considered for diabetes prevention in certain high-risk individuals with prediabetes, particularly those with significant obesity, higher glycaemic values or a history of gestational diabetes.
However, metformin is not routinely required for every individual suspected of having insulin resistance.
More recently, glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies have transformed the management of obesity and type 2 diabetes. These medications can improve metabolic outcomes through effects on appetite regulation, body weight and glucose-dependent hormonal pathways.
Nevertheless, their use should be guided by established clinical indications, individual risk assessment and medical supervision. They should not be considered universal treatments for isolated insulin resistance.
No vitamin, herbal preparation or dietary supplement has been conclusively established as a substitute for evidence-based lifestyle intervention or indicated medical treatment.
Prevention Begins Before Diabetes Develops
A common misconception is that metabolic health requires attention only after blood glucose levels become elevated.
In reality, insulin resistance may precede clinically recognised diabetes by several years, offering an important opportunity for prevention.
Early assessment is particularly valuable for individuals with a family history of type 2 diabetes, increased abdominal adiposity, hypertension, dyslipidaemia, PCOS, previous gestational diabetes or other recognised cardiometabolic risk factors.
Regular physical activity, appropriate nutrition, adequate sleep and maintenance of a healthy body composition can improve metabolic health even before measurable abnormalities develop.
For individuals already diagnosed with prediabetes, structured lifestyle intervention and appropriate clinical follow-up can significantly reduce the likelihood of progression to type 2 diabetes.
The objective is not to pursue a perfect laboratory result or an unrealistic body weight. It is to improve long-term metabolic function through sustainable, evidence-based choices.
Conclusion: Listening to the Body Before the Warning Signs Appear
Insulin resistance illustrates how metabolic disturbances can develop gradually, often without obvious symptoms or immediate changes in blood glucose.
It represents a complex interaction between hormonal regulation, body composition, genetic susceptibility and lifestyle factors, with implications extending from diabetes prevention to cardiovascular, liver and reproductive health.
The most important message is that insulin resistance is not necessarily an irreversible condition. Improvements in physical activity, dietary quality, weight management and overall metabolic health can enhance insulin sensitivity and reduce future disease risk.
Recognising metabolic risk early provides an opportunity to intervene before more serious complications develop.
Ultimately, protecting metabolic health is not simply about controlling blood sugar. It is about supporting the body’s ability to regulate energy efficiently, maintain hormonal balance and preserve long-term wellbeing.
References
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Insulin Resistance & Prediabetes. National Institutes of Health.
https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance -
American Diabetes Association Professional Practice Committee. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
https://doi.org/10.2337/dc26-s003 -
American Diabetes Association Professional Practice Committee. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
https://doi.org/10.2337/dc26-s008 -
Teede HJ, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2447–2469.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10477934/ -
Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. New England Journal of Medicine. 2002;346:393–403.
https://doi.org/10.1056/NEJMoa012512
Medical Disclaimer
This article is intended for educational and informational purposes only and should not be considered a substitute for professional medical advice, diagnosis or treatment. Insulin resistance and associated metabolic disorders require individualised clinical assessment. Readers should consult a qualified healthcare professional before initiating medication, making significant dietary changes or interpreting laboratory results. Treatment decisions should be based on personal medical history, clinical findings and current evidence-based guidelines.